IDeAYA Biosciences weekly recap highlights darovasertib NDA progress
The recap says darovasertib is nearing NDA submission as multiple Phase III trials advance, alongside pipeline momentum from a DLL3 ADC and MTAP/KRAS programs.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.